The U.S. Food and Drug Administration released a new draft guidance for researchers looking into psychedelic medicines to potentially treat medical illnesses, such as psychiatric or substance use disorders, highlighting important factors. This is the first FDA draft guidance offering industry advice on planning clinical trials for psychedelic medications. In recent years, there has been an increase
FDA’s Initial Draft Guidance on Clinical Trials with Psychedelic Drugs
